Recent presentations to brokers and analysts have brought out some interesting statements from the normally very cautious, and restrained, senior management from CST.
Two points stand out:
1. Sales, which have doubled in each of the last four years, are expected to double again in each of the next three years. Since this year looks likely to exceed $20m sales, that means that we can look forward to $160m sales in three years time (with excellent profit margins).
2. The only other competition, world-wide, to replace the century-old skin test for TB, (T-Spot, from Oxford Immunotech), is achieving almost zero sales (about 30 per month).
Sounds like big revenue, protected by wide, Buffet-style, moats.
Regards, Prime
Add to My Watchlist
What is My Watchlist?
